Eli Lilly and Company (LLY)
| Market Cap | 1.04T +31.2% |
| Revenue (ttm) | 79.67B +49.6% |
| Net Income | 26.71B +93.6% |
| EPS | 29.79 +94.8% |
| Shares Out | 891.36M |
| PE Ratio | 39.90 |
| Forward PE | 28.71 |
| Dividend | $6.92 (0.59%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 3,079,239 |
| Open | 1,183.50 |
| Previous Close | 1,188.72 |
| Day's Range | 1,131.21 - 1,186.09 |
| 52-Week Range | 783.85 - 1,292.65 |
| Beta | 0.45 |
| Analysts | Buy |
| Price Target | 1,329.21 (+13.65%) |
| Earnings Date | Oct 29, 2026 |
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial StatementsAnalyst Summary
According to 30 analysts, the average rating for LLY stock is "Buy." The 12-month stock price target is $1,329.21, which is an increase of 13.65% from the latest price.
News
GLP-1s could offer unexpected relief from back and knee pain, but doctors urge caution
Rapid weight loss can lead to issues with bone quality, particularly in older adults.
Eli Lilly price target raised to $1,440 from $1,410 at Cantor Fitzgerald
Cantor Fitzgerald analyst Carter Gould raised the firm’s price target on Eli Lilly (LLY) to $1,440 from $1,410 and keeps an Overweight rating on the shares. Eli Lilly faces a…
Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets
The healthcare sector stood out as one of the few bright spots in Wednesday's trading.
Eli Lilly price target raised to $1,430 from $1,419 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Eli Lilly (LLY) to $1,430 from $1,419 and keeps an Overweight rating on the shares. The firm adjusted its models for its…
Lilly Expands Oncology Footprint With FDA Win for Pancreatic Cancer Drug
Eli Lilly's experimental cancer treatment, olomorasib, receives orphan drug designation from the Food and Drug Administration.
Eli Lilly treatment of pancreatic cancer granted orphan designation
Eli Lilly (LLY) was granted FDA orphan designation for olomorasib for the treatment of pancreatic cancer, according to a post to the agency’s website.
Gate Bioscience expands Lilly drug discovery deal worth more than $870 million
Gate Bioscience said on Monday it expanded a research and licensing agreement with Eli Lilly to develop treatments targeting disease-causing proteins, in a deal potentially worth more than $870 mill...
Eli Lilly expands collaboration, license agreement with Gate Bioscience
Gate Bioscience announced an expansion of its collaboration and license agreement with Eli Lilly (LLY) to discover, develop, and commercialize molecular gate therapeutics. The expanded collaboration a...
Lilly to present new data across its dermatology portfolio with 21 presentations at Fall Clinical 2026, in pursuit of advancing care for chronic skin conditions
Latest EBGLYSS (lebrikizumab-lbkz) data reinforce durable disease control, less frequent maintenance dosing and reduced topical treatment use in patients with moderate-to-severe atopic dermatitis Expl...
An Investor's Guide to Intangible Assets
Although not always easy to quantify, intangible assets are one of the primary sources of strong competitive advantages for businesses and a key source of economic moats. Key Takeaways Intangible asse...
Eli Lilly announces FDA approves additional indication for Jaypirca
Eli Lilly (LLY) and Company announced that the U.S. Food and Drug Administration FDA has approved an additional indication for Jaypirca, a non-covalent Bruton tyrosine kinase inhibitor, for the treatm...
Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL
INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtob...
Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
Eli Lilly and Novo are developing new amylin drugs that serve as another biological lever to pull in treating obesity and diabetes, either as independent treatments or layered on top of existing drugs...
Wedbush downgrades Foghorn on end of Lilly collaboration
Wedbush downgraded Foghorn Therapeutics (FHTX) to Neutral from Outperform with a price target of $2, down from $10, after the company and Eli Lilly (LLY) elected not to advance FHD-909…
Foghorn Therapeutics downgraded at Citizens after FHD-909 discontinuation
As previously reported, Citizens analyst Silvan Tuerkcan downgraded Foghorn Therapeutics (FHTX) to Market Perform from Outperform after the company and partner Eli Lilly (LLY) announced the discontinu...
Trump Medicare drug pricing model may apply to only four companies after exemptions
A Trump administration rule to cut hospital drug prices for Medicare patients may apply to as few as four drugmakers after exempting companies that signed separate "most favored nation" pricing agre...
Foghorn to Slash 40% of Jobs as Lilly Cancer Partnership Falls Apart
Foghorn Therapeutics and Eli Lilly don't plan any future collaborations following the dissolution of a cancer-drug partnership.
Foghorn, Lilly to not advance FHD-909 program, Foghorn to reduce workforce
Foghorn Therapeutics (FHTX) announced that, following a review of clinical data from the Phase 1 dose escalation trial of FHD-909, Foghorn and Lilly (LLY) have decided not to advance the…
Eli Lilly’s Foundayo shows reduction in type 2 diabetes and cardiovascular risk
Eli Lilly (LLY) announced results from post-hoc analyses of ATTAIN-1 showing that Foundayo – orforglipron – was associated with significant reductions in predicted 10-year risk of type 2 diabetes and…
Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease
In post-hoc analyses of ATTAIN-1, Foundayo 17.2 mg was associated with a predicted 57% and 18% reduction in risk of type 2 diabetes and cardiovascular disease vs. placebo Combined with recent research...
Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study
Eli Lilly (LLY) announced detailed results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo – orforglipron – vs. titrated insulin glargine in adults with type…
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the primary objective for non-inferiority compared to insulin glargine In pre-...
Lilly's new weight loss combo drug outperforms tirzepatide in latest trial
Eli Lilly reported positive results from a study following EloraTZP, its experimental combo weight loss drug, noting that patients lost an average of 23.3% of their body weight.
Adding Lilly's new drug to Zepbound helped people lose up to 23% of their weight. But there were more side effects.
The company is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes — much like a GLP-1.
Lilly says participants on EloraTZP lost up to average 23.3% of weight in study
Eli Lilly (LLY) announced “positive” results from a Phase 2b trial evaluating the safety and efficacy of EloraTZP. Eloralintide alone reduced body weight by up to an average of 28.6…